209 related articles for article (PubMed ID: 18519772)
21. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
22. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
[TBL] [Abstract][Full Text] [Related]
23. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
24. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
[TBL] [Abstract][Full Text] [Related]
25. A recent application of fluoro-18-deoxyglucose positron emission tomography, treatment monitoring with a mammalian target of rapamycin inhibitor: an example of a patient with a desmoplastic small round cell tumor.
Dimitrakopoulou-Strauss A; Hohenberger P; Ströbel P; Marx A; Strauss LG
Hell J Nucl Med; 2007; 10(2):77-9. PubMed ID: 17684580
[TBL] [Abstract][Full Text] [Related]
26. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
[TBL] [Abstract][Full Text] [Related]
27. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Nogová L; Boellaard R; Kobe C; Hoetjes N; Zander T; Gross SH; Dimitrijevic S; Pellas T; Eschner W; Schmidt K; Bangard C; Hayes W; Thomas RK; Dietlein M; Giaccone G; Hoekstra OS; Lammertsma AA; Wolf J
J Nucl Med; 2009 Nov; 50(11):1815-9. PubMed ID: 19837761
[TBL] [Abstract][Full Text] [Related]
30. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Habibollahi P; van den Berg NS; Kuruppu D; Loda M; Mahmood U
J Nucl Med; 2013 Feb; 54(2):252-8. PubMed ID: 23376854
[TBL] [Abstract][Full Text] [Related]
31. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma.
Oriuchi N; Tomiyoshi K; Inoue T; Ahmad K; Sarwar M; Tokunaga M; Suzuki H; Watanabe N; Hirano T; Horikoshi S; Shibasaki T; Tamura M; Endo K
J Nucl Med; 1996 Mar; 37(3):457-62. PubMed ID: 8772644
[TBL] [Abstract][Full Text] [Related]
32. In vivo PET/CT in a human glioblastoma chicken chorioallantoic membrane model: a new tool for oncology and radiotracer development.
Warnock G; Turtoi A; Blomme A; Bretin F; Bahri MA; Lemaire C; Libert LC; Seret AE; Luxen A; Castronovo V; Plenevaux AR
J Nucl Med; 2013 Oct; 54(10):1782-8. PubMed ID: 23970367
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Paternot S; Roger PP
Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
[TBL] [Abstract][Full Text] [Related]
34.
Dockx Y; Vangestel C; De Bruycker S; Van den Wyngaert T; Huizing M; Staelens S; Stroobants S
Cancer Biother Radiopharm; 2023 Feb; 38(1):51-61. PubMed ID: 36472460
[No Abstract] [Full Text] [Related]
35. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
[TBL] [Abstract][Full Text] [Related]
37. Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone.
Ebenhan T; Honer M; Ametamey SM; Schubiger PA; Becquet M; Ferretti S; Cannet C; Rausch M; McSheehy PM
Mol Imaging Biol; 2009; 11(5):308-21. PubMed ID: 19462209
[TBL] [Abstract][Full Text] [Related]
38. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.
Direcks WG; Berndsen SC; Proost N; Peters GJ; Balzarini J; Spreeuwenberg MD; Lammertsma AA; Molthoff CF
Br J Cancer; 2008 Aug; 99(3):481-7. PubMed ID: 18665170
[TBL] [Abstract][Full Text] [Related]
39. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography.
Yaghoubi SS; Barrio JR; Namavari M; Satyamurthy N; Phelps ME; Herschman HR; Gambhir SS
Cancer Gene Ther; 2005 Mar; 12(3):329-39. PubMed ID: 15592447
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
